Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer?
Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer?
复制标题
血浆DNA监测能否应用于晚期肺癌患者的个体化化疗？
DOI：
10.1016/j.biopha.2011.11.022
复制
发表时间：
2012-03-01
影响因子：
7.5
通讯作者：
Lu, Shan
中科院分区：
文献类型：
--
作者：
Pan, Shiyang;Xia, Wenying;Lu, Shan
个体化化疗是通常选择的理想治疗方法，有助于提高晚期肺癌患者的生存机会。然而，没有短期评估方案来预测治疗的疗效。本研究旨在探讨血浆DNA在晚期肺癌化疗疗效监测中的应用价值，为临床选择最佳化疗方案提供依据。88名肺癌患者和200名健康对照者被纳入本研究。使用BILATEST DNA试剂盒从具有内部对照的血浆样品中提取血浆DNA。采用双重实时荧光定量PCR法检测血浆DNA含量。一线化疗后，部分缓解患者血浆DNA水平与稳定期和进展期患者比较差异有统计学意义（P = 0.014，P < 0.001和P = 0.418），与健康对照组比较差异无统计学意义（P> 0.05）。生存分析显示，第三周期化疗后血浆DNA水平较低的患者生存时间更长（P = 0.031）。在这项研究中，还观察了整个治疗过程中DNA浓度的动力学与化疗效果的相关性。血浆DNA定量是晚期肺癌患者化疗疗效的敏感指标，可用于预测治疗反应和指导用药。(c)2012年Elsevier Masson SAS。All rights reserved.
Personalized chemotherapy is the ideal treatment usually chosen to help improve the survival chances of patients with advanced lung cancer. However, there is no short-term evaluation protocol for predicting the efficacy of the therapy. The aim of this study was to determine the value of using plasma DNA to monitor chemotherapeutic efficacy and to select most appropriate chemotherapeutic regimen for patients with advanced lung cancer. Eighty-eight lung cancer patients and 200 healthy controls were included in this study. Plasma DNA was extracted from plasma samples with internal controls by using the BILATEST DNA Kit. The quantity of plasma DNA was determined by using duplex real-time quantitative PCR. After first-line chemotherapy, plasma DNA levels of partial response patients were significantly different from those of stable disease patients or progressive disease patients, but with no statistical difference from healthy controls (P = 0.014, P < 0.001 and P = 0.418, respectively). Survival analysis showed a statistically better survival time in patients who had lower levels of plasma DNA after the third cycle chemotherapy (P = 0.031). In this study, the correlation of the kinetics of DNA concentrations with chemotherapeutic efficacy during the whole therapy was also observed. The quantification of plasma DNA is a sensitive indicator of chemotherapeutic efficacy in advanced lung cancer patients, and it can be useful in predicting response to therapy and guiding medication. (c) 2012 Elsevier Masson SAS. All rights reserved.